Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update

Provided By PR Newswire

Last update: Nov 4, 2025

SOUTH SAN FRANCISCO, Calif., Nov. 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the third quarter ended September 30, 2025, including sales of TAVALISSE^® (fostamatinib disodium hexahydrate), GAVRETO^® (pralsetinib) and REZLIDHIA^® (olutasidenib), and recent business progress.

Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update

RIGL Latest News and Analysis

Keep an eye on the top gainers and losers in Wednesday's session.

Wednesday's session: gap up and gap down stocks

These stocks that are showing activity before the opening bell on Wednesday.

What's going on in today's after hours session

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Shows Strong Alignment with Navellier's Growth Criteria

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Presents a Compelling Case for Value Investors